

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

"وَيَسْأَلُونَكَ عَنِ الرُّوحِ قُلِ الرُّوحُ مِنْ أَمْرِ
رَبِّي وَمَا أُوتِيتُمْ مِنَ الْعِلْمِ إِلَّا قَلِيلًا"

صَدَقَ اللَّهُ الْعَظِيمُ

سورة الإسراء "٨٥"

Surgical management of infective endocarditis: Predictors of in-hospital and early outcome

Thesis

**Submitted for partial fulfillment of M.D. Degree in
Cardiothoracic Surgery**

By

Ahmed Mohammed Badr ElDin Ali

(M.B.B.Ch., M.Sc. General Surgery)

Under supervision of

Prof. Dr. El-Sayed Kamel Akl

*Professor of Cardiothoracic Surgery,
Faculty of Medicine, Cairo University*

Prof. Dr. Tarek Ahmed Mohsen

*Professor of Cardiothoracic Surgery,
Faculty of Medicine, Cairo University*

Dr. Ahmed Mohamed El-Ashkar

*Lecturer of Cardiothoracic Surgery,
Faculty of Medicine, Beni-Suef University*

*Faculty of Medicine
Cairo University*

2014

Acknowledgement

At First, I thank God, the most gracious and the most merciful.

*I would like to express my deep thanks to professor Dr. **El-Sayed Akl**, Professor of Cardiothoracic Surgery, Faculty of Medicine, Cairo University, for his continuous guidance, his great support during the preparation of this work. His advices were the cornerstone in the building up of this study. There are no words enough that can express my gratitude to him.*

*I am thankful to professor Dr. **Tarek Mohsen**, Professor of Cardiothoracic Surgery, Faculty of Medicine, Cairo University, for his hearty cooperation, guiding comments, and expert to direct this work step by step.*

*I am very grateful to Dr. **Ahmed El-Ashkar**, Lecturer of Cardiothoracic Surgery, Faculty of Medicine, Beni-Suef University, for his illuminating discussion, constant support.*

No words can express my feelings to my family members.

CONTENTS

	Page
• List of abbreviations.....	iii
• List of tables.....	vi
• List of figures.....	viii
• Introduction and aim of the work.....	1
• Review of literature	
○ Definition and classification.....	4
○ Incidence and epidemiology.....	6
○ Microbiology of IE.....	15
○ Diagnosis.....	27
○ Complications.....	41
○ Antimicrobial therapy.....	51
○ Surgical management of IE.....	69
○ Predictors of mortality in IE.....	97
• Patients and methods.....	123
• Results.....	127
• Discussion.....	155
• Conclusion.....	199
• Study limitations.....	200
• Recommendations.....	201
• Summary.....	202
• References.....	206
• Arabic summary.....	

LIST OF ABBREVIATIONS

AR	Aortic regurgitation
AS	Aortic stenosis
AV	Aortic valve
AVR	Aortic valve replacement
BCNE	Blood culture-negative endocarditis
BMI	Body mass index
CAVH	Cryopreserved aortic viable homograft
CD	Cardiac device
CDRIE	Cardiac device related infective endocarditis
CHD	Congenital heart disease
CHF	Congestive heart failure
CI	Confidence interval
CNS	Central nervous system
CoNS	Coagulase-negative staphylococci
COPD	Chronic obstructive pulmonary disease
CPB	Cardiopulmonary bypass
CRP	C-reactive protein
CT	Computed tomography
CVC	Cerebrovascular complications
DM	Diabetes mellitus
DVT	Deep venous thrombosis
EECC	Estimated endogenous creatinine clearance
EF	Ejection fraction
ESC	European Society of Cardiology
ESR	Erythrocyte sedimentation rate
HAIE	Healthcare-associated IE
Hb	Hemoglobin

HF	Heart failure
HIV	Human immunodeficiency virus
HR	Hazard ratio
IA	Infectious aneurysm
ICD	Implantable cardioverter defibrillator
ICE	International Collaboration on Endocarditis
ICE-PCS	International Collaboration on Endocarditis-Pro prospective Cohort Study
ICU	Intensive care unit
IDUs	Injection drug users
IE	Infective endocarditis
IVDA	Intravenous drug abuser
LV	Left ventricle
MIC	Minimal inhibitory concentration
MR	Mitral regurgitation
MRI	Magnetic resonance imaging
MRSA	Methicillin-resistant <i>Staphylococcus aureus</i>
MS	Mitral stenosis
MSSA	Methicillin-susceptible <i>Staphylococcus aureus</i>
MV	Mitral valve
MVR	Mitral valve replacement
NVE	Native valve endocarditis
NYHA	New York Heart Association
OR	Odds ratio
PASP	Pulmonary artery systolic pressure
PBP	Plasma-binding protein
PCR	Polymerase chain reaction
PET	Positron emission tomography
PPM	Permanent pacemaker
PVE	Prosthetic valve endocarditis
RHD	Rheumatic heart disease

ROC	Receiver operating characteristic
RR	Relative risk
SAM	Subaortic membrane
SD	Standard deviation
STS	Society of Thoracic Surgeons
TEE	Transoesophageal echocardiography
TIA	Transient ischemic attack
TR	Tricuspid regurgitation
TTE	Transthoracic echocardiography
TV	Tricuspid valve
TVR	Tricuspid valve replacement
VISA	Vancomycin-intermediate Staphylococcus aureus
VSD	Ventricular septal defect
WBC	White blood cell

LIST OF TABLES

	Page
Table (1): Classification of infective endocarditis.....	5
Table (2): Microorganisms (%) in Endocarditis by Decade.....	15
Table (3): Clinical presentation of infective endocarditis.....	28
Table (4): Role of echocardiography in infective endocarditis.....	31
Table (5): Investigation of rare causes of culture-negative infective endocarditis.....	38
Table (6): Modified Duke criteria for the diagnosis of infective endocarditis.....	39
Table (7): Factors associated with an increased rate of relapse.....	49
Table (8): Antibiotic treatment of infective endocarditis due to oral streptococci and group D streptococci.....	54
Table (9): Antibiotic treatment of infective endocarditis due to Staphylococcus spp..	60
Table (10): Antibiotic treatment of infective endocarditis due to Enterococcus spp....	63
Table (11): Antibiotic treatment of blood culture-negative infective endocarditis.....	65
Table (12): Proposed antibiotic regimens for initial empirical treatment of infective endocarditis. (before or without pathogen identification).....	67
Table (13): Indications and timing of surgery in left-sided native valve infective endocarditis.....	72
Table (14): Management of neurological complications.....	79
Table (15): Indications and timing of surgery in prosthetic valve infective endocarditis (PVE).....	80
Table (16): Indications for surgical treatment of right-sided infective endocarditis.....	82
Table (17): Predictors of poor outcome in patients with IE.....	122
Table (18): Co-morbidities.....	128
Table (19): Numbers and percentages of different underlying cardiac diseases in IE patients.....	128
Table (20): Echocardiographic findings in IE patients.....	131
Table (21): Laboratory findings in IE patients.....	132

Table (22): Organisms detected in IE patients.....	133
Table (23): Preoperative complications in IE patients.....	134
Table (24): Indications of surgery in IE patients.....	135
Table (25): Operative procedures and types of implanted valves.....	136
Table (26): Causes of in-hospital mortality in IE patients.....	141
Table (27): Major postoperative complications and morbidities.....	142
Table (28): Causes of 6-month mortality in IE patients.....	142
Table (29): Preoperative predictive variables for in-hospital mortality.....	144
Table (30): Preoperative variables not affecting in-hospital mortality.....	144
Table (31): Operative predictive variables for in-hospital mortality.....	147
Table (32): Operative variables not affecting in-hospital mortality.....	147
Table (33): Postoperative predictive variables for in-hospital mortality.....	148
Table (34): Postoperative variables not affecting in-hospital mortality.....	148
Table (35): Independent predictors of in-hospital mortality.....	149
Table (36): Preoperative predictive variables for 6-month mortality.....	150
Table (37): Preoperative variables not affecting 6-month mortality.....	150
Table (38): Operative predictive variables for 6-month mortality.....	153
Table (39): Operative variables not affecting 6-month mortality.....	153
Table (40): Postoperative variables not affecting 6-month mortality.....	154
Table (41): Independent predictors of 6-month mortality.....	154

LIST OF FIGURES

	Page
Figure (1): Indications for echocardiography in suspected infective endocarditis.	32
Figure (2): Large vegetation attached to the AML.....	33
Figure (3): Aortic root abscess.....	33
Figure (4): Microbiological diagnosis in culture-positive and culture-negative infective endocarditis.....	35
Figure (5): Therapeutic strategy for patients with infective endocarditis and neurological complications.....	78
Figure (6): Mechanical aortic valve replacement versus biological aortic valve replacement for endocarditis (STS National Cardiac Database 2007).....	85
Figure (7): Mitral valve repair versus mitral valve replacement for endocarditis (STS National Cardiac Database 2007).....	91
Figure (8): Aortic root replacement using a homograft.....	95
Figure (9): Vegetation and perforation in the medial scallop of the posterior mitral leaflet.....	95
Figure (10): (A) and (B) Double (aortic and mitral) valve endocarditis.....	96
Figure (11): Sex distribution.....	127
Figure (12): Mode of acquisition.....	129
Figure (13): Large vegetations are attached to the right and non-coronary cusps..	138
Figure (14): Aortic root abscess.....	138
Figure (15): Aortic root replacement using a homograft.....	139
Figure (16): Mitral valve endocarditis.....	139
Figure (17): Tricuspid valve endocarditis.....	140
Figure (18): Tricuspid valve replacement using a bioprosthesis.....	140
Figure (19): ROC curve of EuroSCORE II for predicting in-hospital mortality....	146
Figure (20): ROC curve of EuroSCORE II for predicting 6-month mortality.....	152

Aim of the work :

The aim of this study is to audit the surgical experience in the cardiothoracic surgical department, Kasr El-Aini regarding patients with native or prosthetic valve endocarditis and determining predictors of in-hospital and early mortality (6 months following surgery) as an outcome for the primary endpoints in this study which include mortality and recurrence of infection and the need for reoperation within this time frame.

Abstract

Background: Infective endocarditis (IE) is a serious and life threatening disease with significant morbidity and mortality. Despite major advances in diagnostic technology, improvements in antimicrobial selection and monitoring and parallel advances in surgical techniques, the morbidity and mortality due to IE remains high.

Objective: The aim of this study was to audit the surgical experience in the cardiothoracic surgical department, Kasr El-Aini regarding patients with native or prosthetic valve endocarditis and determining predictors of in-hospital and early mortality (6 months following surgery) as an outcome for the primary endpoints in this study which included mortality and recurrence of infection and the need for reoperation within this time frame.

Patients and Methods: Fifty patients diagnosed with definite IE who underwent valve surgery were enrolled in this study. We tested preoperative, intraoperative, and postoperative data as potential predictors of both in-hospital and 6-month mortality.

Results: The in-hospital mortality was 20% and the 6-month mortality was 12.5%. Recurrence of infection occurred in 4% of patients during the follow-up. By multivariate analysis, the independent predictors of in-hospital mortality were CHF (OR=30.914; 95% CI, 2.017 to 473.872; P=0.014), followed by embolization (OR=18.24; 95% CI, 1.935 to 171.906; P=0.011), then periannular extension of infection (OR=12.675; 95% CI, 1.302 to 123.431; P=0.029). Also, by multivariate analysis, periannular extension of infection was the only independent predictor of 6-month mortality (OR=22.667; 95% CI, 1.562 to 328.949; P=0.022). According to the ROC curve, EuroSCORE II > 5.93% is associated with the best predictive value for in-hospital mortality, with a sensitivity of 80%

and a specificity of 75% (area under the curve: 0.813).Also, EuroSCORE II > 5.93% is associated with the best predictive value for 6-month mortality, with a sensitivity of 80% and a specificity of 82.9% (area under the curve: 0.834). Valve repair was associated with lower mortality (11%), excellent durability and resistance to re-infection.

Conclusion: Congestive heart failure, embolization, and periannular extension of infection are the most powerful predictors of in-hospital mortality. Periannular extension of infection is the most powerful predictor of 6-month mortality. EuroSCORE II has a good discrimination ability to predict both in-hospital and 6-month mortality in IE surgery. Satisfactory results can be obtained with valve repair in IE.

Keywords: Infective endocarditis, Surgery, Predictors, Mortality, EuroSCORE II, Valve repair

Introduction

Infective endocarditis (IE), or infection of an endocardial surface of the heart, remains an uncommon disease associated with significant morbidity, including complications of heart failure, stroke, systemic embolization, and sepsis. Despite continued progress in the diagnosis and treatment of this condition, IE continues to have an in-hospital mortality of approximately 20%, essentially unchanged over the past 2 decades (*Murdoch et al., 2009*).

Antibiotics contributed to an improvement in survival, but also changed the major cause of death from infection to congestive heart failure. Although antibiotics remain the first line treatment of bacterial endocarditis, it becomes insufficient when complications develop. Under these circumstances mortality rates are unacceptable with medical treatment alone (50-90%), when compared to surgery (30%) (*Dodge et al., 1995; Alexiou et al., 2000*).

Surgery is potentially lifesaving (*Olaison and pettersson, 2002*), and is required in 25% to 50% of cases during acute infection and 20% to 40% during convalescence (*Jault et al., 1997; Castillo et al., 2000; Wang et al., 2007; Murdoch et al., 2009*). Overall surgical mortality in active IE is 6% to 25%, with long-term survival rates of approximately 70% in most series (*Revilla et al., 2007; Slater et al., 2007; Tleyjeh et al., 2008; Murdoch et al., 2009; Thuny et al., 2011*).

The goals of surgical therapy are as follows: 1) to eradicate the infection; 2) to repair cardiac destruction; 3) to prevent the development of complications and relapse of infection; 4) to offer a survival advantage to medical therapy alone, when indicated (*Delahaye et al., 2004*).

The indications for and the timing of surgery remain controversial as there are few randomized trials to guide patient management (*Kang and Smith, 2013*). Reasons to consider early surgery in the active phase, i.e. while the patient is still receiving antibiotic treatment, are to avoid progressive HF and irreversible structural damage caused by severe infection and to prevent systemic embolism (*Delahaye et al., 2004; Baddour et al., 2005; Aksoy et al., 2007; Thuny et al., 2011*). On the other hand, surgical therapy during the active phase of the disease is associated with significant risk. Surgery is justified in patients with high-risk features which make the possibility of cure with antibiotic treatment unlikely and who do not have co-morbid conditions or complications which make the prospect of recovery remote (*Habib et al., 2009*).

Identification of patients requiring early surgery is frequently difficult. Each case must be individualized and all factors associated with increased risk identified at the time of diagnosis. Frequently, the need for surgery will be determined by a combination of several high-risk features (*Thuny et al., 2011*).

The results of surgery depend upon many factors. The general preoperative condition of the patient, antibiotic treatment, timing of surgery, perioperative management, surgical techniques (including choice of valve replacement versus repair, type of valve and methods of reconstruction), postoperative management, and follow up are all important determinants of outcome. Preoperative New York Heart Association (NYHA) classification, age, and preoperative renal failure are common predictors of operative mortality (*Olaison and pettersson, 2002*).